Great news! On May 18, Bio-Thera's recombinant humanized anti-VEGF monoclonal antibody injection (BAT1706) was approved for clinical trials by the China Food and Drug Administration (CFDA), marking our second approval for biosimilar clinical trials this year. BAT1706 is a bevacizumab biosimilar indicated for use in the treatment of many types of tumors, including colorectal cancer, non-small cell lung cancer, breast cancer, malignant glioma, renal cell carcinoma, and ovarian cancer. Bio-Thera is currently implementing a global development plan for BAT1706, and phase I trials have already commenced in New Zealand, making this the first clinical study of a bevacizumab biosimilar to be conducted overseas by a Chinese company.